Michael Burkes Brophy Sells 1,866 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 1,866 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $93.97, for a total value of $175,348.02. Following the completion of the sale, the chief financial officer now owns 67,542 shares in the company, valued at $6,346,921.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, April 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $93.14, for a total value of $115,307.32.
• On Thursday, April 25th, Michael Burkes Brophy sold 705 shares of Natera stock. The stock was sold at an average price of $89.55, for a total value of $63,132.75.
• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The stock was sold at an average price of $91.38, for a total value of $139,171.74.
• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The stock was sold at an average price of $92.62, for a total value of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The stock was sold at an average price of $90.42, for a total value of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The shares were sold at an average price of $88.36, for a total value of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total value of $2,383,050.87.

Natera Stock Up 3.5 %

NTRA opened at $96.98 on Friday. The business’s fifty day moving average is $90.56 and its two-hundred day moving average is $69.48. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. Natera, Inc. has a one year low of $36.90 and a one year high of $98.82.

Natera (NASDAQ:NTRA) last posted its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. The company had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. As a group, equities analysts forecast that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on NTRA. Canaccord Genuity Group lifted their price objective on Natera from $87.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, February 29th. Raymond James lowered Natera from a “strong-buy” rating to an “outperform” rating and lifted their price objective for the company from $68.00 to $85.00 in a report on Tuesday, February 20th. Stephens reaffirmed an “overweight” rating and issued a $78.00 price objective on shares of Natera in a report on Tuesday, January 30th. The Goldman Sachs Group lifted their price objective on Natera from $90.00 to $100.00 and gave the company a “buy” rating in a report on Monday, April 15th. Finally, Sanford C. Bernstein raised Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective on the stock in a report on Friday, April 5th. One equities research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $86.40.

Hedge Funds Weigh In On Natera

A number of institutional investors have recently made changes to their positions in NTRA. RiverPark Advisors LLC acquired a new position in shares of Natera in the fourth quarter worth $27,000. Principal Securities Inc. acquired a new position in shares of Natera in the fourth quarter worth $32,000. YHB Investment Advisors Inc. acquired a new position in shares of Natera in the first quarter worth $36,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Natera in the third quarter worth $44,000. Finally, Oliver Lagore Vanvalin Investment Group increased its stake in Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 389 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.